Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis

Authors: Yubin Liu, Sujuan Kuang, Jun Zheng, Jianghua Zheng, Haosheng Jin, Sicong Chen, Zhixiang Jian

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Murine double minute 2 (MDM2) is a crucial negative regulator of p53 function through several mechanisms. There are many studies performed to assess the association between MDM2 rs2279744 polymorphism and hepatocellular carcinoma risk, but the impact of MDM2 rs2279744 polymorphism on hepatocellular carcinoma in East Asians is unclear owing to the inconsistent findings from previous studies. We conducted a comprehensive meta-analysis of epidemiological studies to shed some light on these contradicting results. We used pooled odds ratio (OR) with its 95 % confidence intervals (95 % CI) to assess the association. Overall, seven studies with a total of 4,993 subjects were finally included. The meta-analysis suggested that MDM2 rs2279744 polymorphism was significantly associated with increased risk of hepatocellular carcinoma in East Asians (G versus T: OR = 1.27, 95 % CI 1.06–1.52, P = 0.01; GG versus TT: OR = 1.59, 95 % CI 1.11–2.27, P = 0.01; GG/GT versus TT: OR = 1.41, 95 % CI 1.07–1.87, P = 0.02; GG versus TT/GT: OR = 1.32, 95 % CI 1.08–1.62, P = 0.008). Sensitivity analysis by excluding low-quality study still suggested that the association above was still significant. Thus, the findings from the meta-analysis support that MDM2 rs2279744 polymorphism is significantly associated with increased risk of hepatocellular carcinoma in East Asians.
Literature
2.
go back to reference Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology. 1998;27:1567–71.PubMedCrossRef Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology. 1998;27:1567–71.PubMedCrossRef
3.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
5.
go back to reference Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012;61 Suppl 1:i25–35.PubMedCrossRef Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012;61 Suppl 1:i25–35.PubMedCrossRef
6.
7.
go back to reference Asim M, Malik A, Ahmad I, Khan NA, Kar P. Association of TNF alpha promoter polymorphism with an increased risk of hepatocellular carcinoma in north Indian population. Hepatol Int. 2011;5:428. Asim M, Malik A, Ahmad I, Khan NA, Kar P. Association of TNF alpha promoter polymorphism with an increased risk of hepatocellular carcinoma in north Indian population. Hepatol Int. 2011;5:428.
8.
go back to reference Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRef Wang B, Huang G, Wang D, Li A, Xu Z, Dong R, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol. 2010;53:508–18.PubMedCrossRef
9.
go back to reference Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303.PubMedCrossRef Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303.PubMedCrossRef
10.
go back to reference Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7–10.PubMed Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7–10.PubMed
11.
go back to reference Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8:25–37.PubMedCrossRef Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8:25–37.PubMedCrossRef
12.
go back to reference Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010;29:4253–60.PubMedCrossRef Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010;29:4253–60.PubMedCrossRef
13.
go back to reference Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem. 2010;17:3142–54.PubMedCrossRef Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem. 2010;17:3142–54.PubMedCrossRef
14.
go back to reference Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMedCrossRef Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMedCrossRef
15.
go back to reference Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262–7.PubMedCrossRef Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262–7.PubMedCrossRef
16.
go back to reference Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12:4867–71.PubMedCrossRef Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12:4867–71.PubMedCrossRef
17.
go back to reference Jiang D, Yu L: P53 gene mutation, r72p polymorphism and mdm2 snp309 gene polymorphism and HCC risk and prognosis. Wanfang Doctoral Dissertation 2008;2008:2008. Jiang D, Yu L: P53 gene mutation, r72p polymorphism and mdm2 snp309 gene polymorphism and HCC risk and prognosis. Wanfang Doctoral Dissertation 2008;2008:2008.
18.
go back to reference Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–6.PubMedCrossRef Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–6.PubMedCrossRef
19.
go back to reference Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15:5592–7.PubMedCrossRef Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15:5592–7.PubMedCrossRef
20.
go back to reference Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, et al. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol. 2012;27:797–804.PubMedCrossRef Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, et al. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol. 2012;27:797–804.PubMedCrossRef
21.
go back to reference Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.PubMedCrossRef
22.
go back to reference Yang Y, Xia T, Li N, Zhang J, Cong W, Deng Q, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4:71–81.PubMedCrossRef Yang Y, Xia T, Li N, Zhang J, Cong W, Deng Q, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4:71–81.PubMedCrossRef
23.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
24.
25.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
26.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
27.
go back to reference He W, Long J, Xian L, Pang F, Su L, Wei S, et al. MDM2 SNP309 polymorphism is associated with lung cancer risk in women: a meta-analysis using METAGEN. Exp Ther Med. 2012;4:569–76.PubMedCentralPubMed He W, Long J, Xian L, Pang F, Su L, Wei S, et al. MDM2 SNP309 polymorphism is associated with lung cancer risk in women: a meta-analysis using METAGEN. Exp Ther Med. 2012;4:569–76.PubMedCentralPubMed
Metadata
Title
Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis
Authors
Yubin Liu
Sujuan Kuang
Jun Zheng
Jianghua Zheng
Haosheng Jin
Sicong Chen
Zhixiang Jian
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1128-x

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine